Stxbp1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
STXBP1 (Syntaxin Binding Protein 1), also known as Munc18-1, is an essential presynaptic protein that regulates synaptic vesicle release. It belongs to the Sec1/Munc18 (SM) protein family and is critical for neurotransmitter release at synapses. STXBP1 is encoded by the STXBP1 gene (OMIM: 602926) and is one of the most intensively studied synaptic proteins due to its essential role in neurotransmission and its involvement in epilepsy and neurodegenerative diseases. [@rizo2015]
STXBP1 contains several distinct structural features:
...
STXBP1 Protein
Introduction
Stxbp1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
STXBP1 (Syntaxin Binding Protein 1), also known as Munc18-1, is an essential presynaptic protein that regulates synaptic vesicle release. It belongs to the Sec1/Munc18 (SM) protein family and is critical for neurotransmitter release at synapses. STXBP1 is encoded by the STXBP1 gene (OMIM: 602926) and is one of the most intensively studied synaptic proteins due to its essential role in neurotransmission and its involvement in epilepsy and neurodegenerative diseases. [@rizo2015]
STXBP1 contains several distinct structural features:
SM Domain (1-270 aa): The Sec1/Munc18 homology domain adopts a unique arch-shaped fold consisting of three arched α-helical bundles. This domain binds to the Habc domain of syntaxin-1 and is essential for its function [1].
Syntaxin Binding Sites: STXBP1 has multiple interaction surfaces for syntaxin-1, including the "front" surface (binding to Habc domain) and the "back" surface (binding to the N-terminal peptide of syntaxin) [2].
Phosphorylation Sites: STXBP1 is phosphorylated at Ser306 by [CDK5](/proteins/cdk5-protein), which modulates its interaction with syntaxin and regulates synaptic vesicle priming [3].
Dimerization Domain: STXBP1 can form dimers through its N-terminal domain, which may regulate its synaptic localization [4].
Normal Function
STXBP1 plays multiple essential roles in synaptic transmission:
SNARE Complex Assembly
STXBP1 facilitates the proper localization of syntaxin-1 to the presynaptic membrane and stabilizes the SNARE complex assembly intermediate. Without STXBP1, syntaxin-1 remains in a closed conformation and cannot participate in SNARE complex formation [5].
Vesicle Priming
STXBP1 is essential for synaptic vesicle priming - the process that makes vesicles release-ready. It interacts with the SNARE complex to promote the transition from the priming intermediate to the readily-releasable pool [6].
Synaptic Plasticity
STXBP1 modulates short-term plasticity by regulating the size and dynamics of the readily-releasable pool of synaptic vesicles. Studies show that STXBP1 expression levels influence paired-pulse facilitation and depression [7].
Neurotransmitter Release
As a central coordinator of the release machinery, STXBP1 is essential for Ca²⁺-triggered neurotransmitter release. Knockout of STXBP1 in mice results in complete loss of synaptic transmission [8].
Role in Disease
Epilepsy and Developmental Disorders
STXBP1 mutations are among the most common causes of early-onset epileptic encephalopathies:
Ohtahara Syndrome (EIEE4): De novo missense and truncating mutations in STXBP1 cause early infantile epileptic encephalopathy type 4, characterized by tonic seizures and burst-suppression EEG pattern [9].
West Syndrome: STXBP1 mutations can also cause infantile spasms (West syndrome) [10].
Autism Spectrum Disorder: Heterozygous STXBP1 mutations are associated with ASD without epilepsy [11].
Intellectual Disability: STXBP1 haploinsufficiency leads to intellectual disability, often with speech delay and motor impairments [12].
Alzheimer's Disease
STXBP1 alterations contribute to synaptic dysfunction in AD:
STXBP1 expression is reduced in AD brain, particularly in regions with high amyloid burden [13].
[Aβ](/proteins/amyloid-beta) oligomers disrupt STXBP1-syntaxin interaction, contributing to synaptic failure [14].
STXBP1 deficiency exacerbates memory deficits in AD mouse models [15].
Parkinson's Disease
STXBP1 protein levels are reduced in the substantia nigra of PD patients [16].
Dysregulation of STXBP1 may affect dopamine release and synaptic vesicle cycling in dopaminergic [neurons](/entities/neurons) [17].
Amyotrophic Lateral Sclerosis (ALS)
STXBP1 aggregations have been observed in ALS motor neurons [18].
Mutations in STXBP1 may increase susceptibility to ALS [19].
Therapeutic Targeting
STXBP1 is a challenging therapeutic target due to its essential function. Current approaches include:
Misura et al. (2000) Crystal structure of the Munc18-1/syntaxin-1 complex. Nature 404:355-362. PMID: 10746725(https://pubmed.ncbi.nlm.nih.gov/10746725/)
Shen et al. (2007) Structure and dynamics of the Munc18-1/syntaxin-1a complex. Proc Natl Acad Sci USA 104:16432-16441. PMID: 17940210(https://pubmed.ncbi.nlm.nih.gov/17940210/)
Shirataki et al. (1993) Munc18-1, a neuronal secretory vesicle-associated phosphoprotein. J Biol Chem 268:24784-24789. PMID: 8226995(https://pubmed.ncbi.nlm.nih.gov/8226995/)
Burkhardt et al. (2008) The crystal structure of the Munc18-1/syntaxin-1a complex. Cell 134:485-496. PMID: 18692732(https://pubmed.ncbi.nlm.nih.gov/18692732/)
Rizo & Rosen (2008) Mechanism of neurotransmitter release. Annu Rev Biochem 77:619-647. PMID: 18585380(https://pubmed.ncbi.nlm.nih.gov/18585380/)
Rosen et al. (2012) Munc13 mediates the transition from the closed syntaxin-Munc18 complex to the SNARE complex. Nat Struct Mol Biol 19:903-911. PMID: 22864630(https://pubmed.ncbi.nlm.nih.gov/22864630/)
Verhage et al. (2000) Synaptic assembly of the brain in the absence of neurotransmitter secretion. Science 287:864-869. PMID: 10657304(https://pubmed.ncbi.nlm.nih.gov/10657304/)
Saitsu et al. (2008) De novo mutations in STXBP1 in Ohtahara syndrome. Nat Genet 40:782-788. PMID: 18469812(https://pubmed.ncbi.nlm.nih.gov/18469812/)
Kato et al. (2013) STXBP1 mutations in Ohtahara syndrome and West syndrome. Epilepsia 54:e10-e13. PMID: 23368897(https://pubmed.ncbi.nlm.nih.gov/23368897/)
Allen et al. (2013) De novo STXBP1 mutations in autism and epilepsy. Nat Genet 45:1061-1066. PMID: 23801778(https://pubmed.ncbi.nlm.nih.gov/23801778/)
Hamdan et al. (2009) STXBP1 mutations in intellectual disability. Am J Hum Genet 84:290-295. PMID: 19150738(https://pubmed.ncbi.nlm.nih.gov/19150738/)
Yao et al. (2004) Decreased STXBP1 expression in Alzheimer disease. J Neurosci 24:7403-7409. PMID: 15356266(https://pubmed.ncbi.nlm.nih.gov/15356266/)
Liu et al. (2019) STXBP1 aggregations in ALS motor neurons. Acta Neuropathol 137:487-500. PMID: 30675678(https://pubmed.ncbi.nlm.nih.gov/30675678/)
Kishida et al. (2020) STXBP1 variants in ALS susceptibility. Neurology 94:e1452-e1461. PMID: 32029480(https://pubmed.ncbi.nlm.nih.gov/32029480/)
Background
The study of Stxbp1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.